SlipstreamJobs tracks this role from the company's public career site. Apply directly on the employer's site.
Raven StealthCo, incubated by RA Capital's venture group, is a well-funded stealth-mode biotechnology company developing next-generation oligonucleotide-based therapeutics targeting tissues beyond the liver, muscle, and kidney. The company is building a precision delivery platform for oligonucleotides to previously untargeted cells, focusing on "undruggable" genes alone or in combination with validated targets. Headquartered in Cambridge, Massachusetts, the company aims to create transformational therapies for diseases with multi-billion-dollar market potential, with longer-term ambitions in healthy aging.
The Principal Scientist, In Vivo Pharmacology will lead the company's in vivo pharmacology efforts, reporting to the Director of Biology and Pharmacology. This is an individual contributor role at hire with clear expansion potential as the portfolio and team grow. The role focuses on design, direction, and interpretation of externally executed studies rather than hands-on execution.
Key responsibilities include: partnering with the Director to set and execute the staged in vivo pharmacology plan from target validation through candidate selection; designing CRO-executed rodent and non-human-primate studies with appropriate controls, power calculations, and pre-specified endpoints; authoring protocols and analysis plans; qualifying and managing CRO partners for in vivo studies and outsourced analytics; selecting and de-risking in vivo models; and owning the in vivo endpoint suite including quantitative histology, morphometry, and tissue-based pharmacodynamic readouts. The successful candidate will serve as the day-to-day scientific contact for study design, CRO scoping and oversight, sample logistics, tissue-processing support, and data interpretation. The role requires translating overall biology and pharmacology strategy into rigorous in vivo programs and driving execution end-to-end, with studies leveraging highly predictive animal models offering rapid and efficient paths to clinical translation.
